RxDoctor Payments Data

Jeniffer Torres-Velazco, MD

Internal Medicine · Tampa, FLNPI 1568781953

Payments from drug & device makers

$2,028in general payments, 2019–2025

Across 76 payments — averaging $26.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$524
  • AbbVie$294
  • Astellas Pharma US Inc$254
  • Takeda Pharmaceuticals U.S.A., Inc.$211
  • Merck$179
  • Melinta Therapeutics, LLC$150
  • plus $415 from 9 others

What the payments were for

  • Food & beverage$1,81389%
  • Education$21411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,028 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$170,324
Medicare patients
483
Services billed
30,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala47$191,118
GenvoyaElviteg/Cob/Emtri/Tenof Alafen33$150,656
TivicayDolutegravir Sodium49$106,190
DovatoDolutegravir Sodium/Lamivudine26$73,379
OdefseyEmtricitab/Rilpiviri/Tenof Ala20$69,214
TeflaroCeftaroline Fosamil Acetate13$68,042
IsentressRaltegravir Potassium25$47,710
PifeltroDoravirine15$26,721
DescovyEmtricitabine/Tenofov Alafenam12$26,334
Daptomycin22$23,444
VemlidyTenofovir Alafenamide12$16,268
Posaconazole11$14,317
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)25$9,057
Abacavir-LamivudineAbacavir Sulfate/Lamivudine13$7,260
ErtapenemErtapenem Sodium11$5,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Vemlidy$113$384,377104 claims
Viiv Healthcare CompanyTivicay, Dovato$78$179,56975 claims
MerckIsentress, Pifeltro$179$74,43240 claims
AbbVieTeflaro$294$68,04213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →